ZERO TO I BIOSCIENCES develops magnetic nanomedicine therapeutics that utilize a nano-carrier platform to target and eliminate cancer cells in the body. This technology minimizes the side effects associated with traditional cancer treatments, providing a more effective and less invasive option for patients.
Funding
$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often lack precision, leading to systemic toxicity and harmful side effects due to their impact on healthy cells. This can result in reduced quality of life for patients and limit the effectiveness of therapy.
Solution
ZERO TO I BIOSCIENCES is developing targeted cancer therapeutics using a nano-carrier platform called TERACARRIER™ to deliver radiopharmaceuticals directly to cancer cells. This approach aims to minimize damage to healthy tissues, reducing side effects and improving treatment outcomes. The TERACARRIER™ platform facilitates the development of standardized radiopharmaceuticals, potentially accelerating the drug development process and expanding the availability of targeted cancer therapies.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and ultimately, cancer patients seeking more effective and less invasive treatment options.
Features
- TERACARRIER™ nano-carrier platform for targeted drug delivery
- Radiopharmaceutical therapeutics for cancer treatment
- Potential for reduced side effects compared to traditional chemotherapy
- Standardized radiopharmaceutical development process